[1]Luckman SP,Coxon FP,Ebetion FH,et al.Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation:evidence from structure-activity relationships in J774 macrophages[J].J Bone Miner Res,1998,13(11):1668-1678.
[2]Dunford JE,Thompson K,Coxon FP,et al.Structure-activityrelationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogencontaining bisphosphonates[J].J Pharmacol Exp Ther,2001,296(2):235-242.
[3]Lee MV,Fong EM,Singer FR,et al.Bisphosphonate treatment inhibits the growth of prostate cancer cells[J].Cancer Res,2001,61(6):2602-2608.
[4]Daubiné F,Le Gall C,Gasser J,et al.Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis[J].J Natl Cancer Inst,2007,99(4):322-330.
[5]Ottewell PD,Wang N,Brown HK,et al.Zoledronic acid has differential antitumor activity in the pre-and postmenopausal bone microenvironment in vivo[J].Clin Cancer Res,2014,20(11):2922-2932.
[6]Kijima T,Koga F,Fujii Y,et al.Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1[J].PLoS One,2013,8(5):e64615.
[7]Gnant M,Mlineritsch B,Stoeger H,et al.Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with earlystage breast cancer:62-month follow-up from the ABCSG-12 randomised trial[J].Lancet Oncol,2011,12(7):631-641.
[8]Fukai J,Koizumi F,Nakao N.Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase[J].PLoS One,2014,9(8):e104538.
[9]Thurnher M,Nussbaumer O,Gruenbacher G.Novel aspects of mevalonate pathway inhibitors as antitumor agents[J].Clin Cancer Res,2012,18(13):3524-3531.
[10]Castella B,Riganti C,Fiore F,et al.Immune modulation by zoledronic acid in human myeloma:an advantageous crosstalk between Vγ9Vδ2 T cells,αβ CD8+ T cells,regulatory T cells,and dendritic cells[J].J Immunol,2011,187(4):1578-1590.
[11]Kiper HD,Tezcanli Kaymaz B,Gokbulut AA,et al.STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells[J].Biomed Pharmacother,2013,67(6):527-532.
[12]Misso G,Porru M,Stoppacciaro A,et al.Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid[J].Cancer Biol Ther,2012,13(14):1491-1500.
[13]肖德明,王大平,张世权.简明骨与软组织肿瘤学[M].广州:华南理工大学出版社,2006:90-102.
[14]Chou AJ,Geller DS,Gorlick R.Therapy for osteosarcoma:where do we go from here?[J].Paediatr Drugs,2008,10(5):315-327.
[15]Rosen G,Marcove RC,Caparros B,et al.Primary osteogenic sarcoma:the rationale for preoperative chemotherapy and delayed surgery[J].Cancer,1979,43(6):2163-2177.
[16]Meyers PA,Schwartz CL,Krailo MD,et al.Osteosarcoma:the addition of muramyl tripeptide to chemotherapy improves overall survival——a report from the Children's Oncology Group[J].J Clin Oncol,2008,26(4):633-638.
[17]Longhi A,Ferrari S,Bacci G,et al.Long-term followup of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma[J].Anticancer Drugs,2007,18(6):737-744.
[18]Abe S,Nishimoto Y,Isu K,et al.Preoperative cisplatin for initial treatment of limb osteosarcoma:its local effect and impact on prognosis[J].Cancer Chemother Pharmacol,2002,50(4):320-324.
[19]Woodward JK,Neville-webbe HL,Coleman RE,et al.Combined Effects of zoledronic acid and doxorubicin on breastcancer cell invasion invitro[J].Anticancer Drugs,2005,16(8):845 -854.
[20]Nevillewebbe HL,RostamiHodjegan A,Evans CA,et al.Sequence-and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells[J].Int J Cancer,2005,113(3):364-371.
[21]Iguchi T,Miyakawa Y,Saito K,et al.Zoledronate-induced Sphase Arrest and apoptosis accompanied by DNA damage and activation of The ATM/Chk1/cdc25 pathway inhuman osteosarcoma cells[J].Int J Oncol,2007,31(2):285-291.
[22]Di Carlo E,Bocca P,Emionite L,et al.Mechanisms of the antitumor activity of human Vgamma9Vdelta2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma[J].Mol Ther,2013,21(5):1034-1043.
[23]Fleisch H.Development of bisphosphonates[J].Breast Cancer Res,2002,4(1):30-34.
[24]Evdokiou A,Labrinidis A,Bouralexis S,et al.Induction of cell death of human osteogenic sarcoma cells by zoledronicacid resembles anoikis[J].Bone,2003,33(2):216-228.
[25]Horie N,Murata H,Kimura S,et al.Combine deffects of a third generation bisphosphonate,zoledronic acid with other anticancer agents again stmurine osteosarcoma[J].Br J Cancer,2007,96(2):255 -261.
[26]Benassi MS,Chiechi A,Ponticelli F,et al.Growth inhibition and sensitization to cisplatinby zoledronic acid in osteosarcoma cells[J].CancerLett,2007,250(2):194 -205.